While individual results vary, we typically see patients maintain steady weight loss throughout their first year of treatment
Increased risk of severe acute pancreatitis in patients with diabetes
For instance, in October 2024, Novo Nordisk made significant strides with Rybelsus, as the company announced its plan to expand the drugs indication to prevent major adverse cardiovascular events (MACE) in patients with Type 2 diabetes, cardiovascular disease (CVD), or chronic kidney disease (CKD)
Others, like CJC-1295, ipamorelin, and MOTS-c, may support fat burning and metabolism indirectly
However, this depends heavily on how insurers, pharmacies, and drug manufacturers structure pricing, which can vary widely